Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Financial Officer | September 15, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 164,096 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 3,000 · Balance 164,096 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 356 | $72.34 | $25,753.04 |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 15, 2020 Filed Mar 13, 2020 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 395 | $53.67 | $21,199.26 |
DisclosureSEC source: 0001127602-20-010511 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,987 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2019 through February 15, 2020. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2020. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 19:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004544 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 Underlying: Common Stock · 1,818 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 19:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 599 | $68.21 | $40,857.79 |
DisclosureSEC source: 0001127602-20-004544 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,592 Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 19:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004544 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 3,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-002968 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,373 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2018, and February 6, 2019. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| November 10, 2019 Filed Nov 12, 2019 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-032568 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,439 Underlying: Common Stock · 1,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on the anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on the anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2019 Filed Nov 12, 2019 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 7,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-032568 · form4.xml · derivative · entry 4 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,164 Underlying: Common Stock · 7,650 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2019 Filed Nov 12, 2019 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 44,160 | $0.00 Strike: $65.38 | $0.00 |
DisclosureSEC source: 0001127602-19-032568 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,160 Underlying: Common Stock · 44,160 shares Expires 2029-11-10 F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 10, 2019 Filed Nov 12, 2019 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 521 | $65.38 | $34,062.98 |
DisclosureSEC source: 0001127602-19-032568 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,539 Read SEC document |
| November 10, 2019 Filed Nov 12, 2019 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-032568 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.